Key Developments: Johnson & Johnson (JNJ)

JNJ on New York Consolidated

22 Jul 2014
Price Change (% chg)

$1.20 (+1.18%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson gives FY 2014 EPS guidance
Tuesday, 21 Jan 2014 07:45am EST 

Johnson & Johnson:Sees FY 2014 of $5.75 to $5.85 per share, which excludes the impact of special items.FY 2014 EPS of $5.85 - Thomson Reuters I/B/E/S.  Full Article

U.S. FDA panel rejects Johnson & Johnson drug for acute coronary syndrome-Reuters
Thursday, 16 Jan 2014 05:32pm EST 

Johnson & Johnson:Says that its anticoagulant Xarelto should not be approved to prevent further heart problems in patients who have recently suffered a heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Jan 16-Reuters.Says panel voted 10 to 0, with one abstention, that data presented by the company from a single clinical trial was not strong enough to justify approval, especially since some data from was missing.Says.  Full Article

Carlyle Group LP agrees to acquire Johnson & Johnson’s Ortho-Clinical Diagnostics for $4.15 bln
Thursday, 16 Jan 2014 07:45am EST 

Carlyle Group LP:Says it has agreed to acquire Johnson & Johnson`s Ortho-Clinical Diagnostics (OCD) business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 bln.Says the transaction is subject to customary regulatory approvals and is expected to close in the middle of 2014.  Full Article

Johnson & Johnson announces quarterly dividend
Thursday, 2 Jan 2014 08:30am EST 

Johnson & Johnson:Says it has declared a cash dividend for the first quarter of 2014 of $0.66 per share on the company's common stock.Says the dividend is payable on Mar. 11 to shareholders of record at the close of business on Feb. 25.Says the ex-dividend date is Feb. 21.  Full Article

EU regulators fine Johnson & Johnson, Novartis AG 16 mln euros for generic drug deal - Reuters
Tuesday, 10 Dec 2013 09:00am EST 

Johnson & Johnson and Novartis AG:European Union antitrust regulators fined Johnson & Johnson .N and Novartis AG a total of 16 million euros ($21.95 million) on Dec. 10 for blocking the sale of a generic painkiller in the Dutch market - Reuters.The European Commission said in a statement that the deal between the two companies meant patients did not have access to the cheaper generic version of fentanyl for 17 months starting from July 2005.Johnson & Johnson and its Dutch unit, Janssen-Cilag, were fined 10.8 million euros while Novartis and its Dutch subsidiary, Sandoz, were fined 5.5 million euros.  Full Article

Johnson & Johnson's Unit To Pay $2.5 Billion In U.S. Hip Implant Settlement-Reuters
Tuesday, 19 Nov 2013 05:18pm EST 

Reuters reported that a unit of Johnson & Johnson has agreed to pay an estimated $2.5 billion to settle thousands of lawsuits from individuals allegedly injured by the Company’s artificial hip implants. The settlement would compensate an estimated 8,000 patients who underwent surgery to replace their hip implants, according to a statement from Johnson & Johnson unit Depuy Orthopaedics Inc and lawyers for the plaintiffs.  Full Article

Johnson & Johnson To Reach $4 Billion Deal On Hip Implant Lawsuits - Reuters
Tuesday, 12 Nov 2013 04:47pm EST 

Reuters reported that Johnson & Johnson will pay more than $4 billion to settle thousands of lawsuits over its recalled defective hip implants. The deal will resolve more than 7,500 lawsuits in federal and state courts by patients who have already had the defective devices removed, the report said.  Full Article

Danaher Corp, Blackstone Group LP Team Up To Bid For Johnson & Johnson's Diagnostics Unit-Reuters
Thursday, 7 Nov 2013 05:33pm EST 

Reuters reported that Danaher Corp has teamed up with Blackstone Group LP to bid for Johnson & Johnson's diagnostics unit, which makes blood screening equipment and laboratory blood tests and could fetch more than $4 billion. Blackstone, declined to comment. Representatives for J&J, Danaher did not immediately respond to requests for comment.  Full Article

Johnson & Johnson To Pay $2.2 Billion To End U.S. Marketing Probes-Reuters
Monday, 4 Nov 2013 10:30am EST 

Reuters reported that Johnson & Johnson will pay $2.2 billion to the U.S. government to end multiple investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses. The settlement with the Company and its subsidiaries covers the marketing of schizophrenia treatment Risperdal and of heart drug Natrecor.  Full Article

FDA Advisory Panel Backs Approval Of Johnson & Johnson's Hepatitis C Drug-Reuters
Thursday, 24 Oct 2013 04:36pm EDT 

Reuters reported that an advisory committee of the U.S. Food and Drug Administration voted unanimously to approve Johnson & Johnson's hepatitis C drug. The panel voted 19-0 in favor of the drug, simeprevir, which was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin. The drug is being developed by J&J unit Janssen Research & Development LLC. It is being tested in adults who failed previous interferon-based therapy or had not received medication at all. The FDA usually follows the recommendation of the advisory panel, although it is not obligated to do so. Hepatitis C, an infection of the liver transmitted through the blood, kills more than 15,000 Americans each year, mostly from hepatitis C-related illnesses such as cirrhosis and liver cancer.  Full Article

Search Stocks